Chenglai Medicine(Beijing)Co.LTD, headquartered in Airport Science and Technology Park, Shunyi District, Beijing, focuses on the field of minimally invasive urological surgery and is committed to bringing internationally advanced urological health solutions to Chinese patients.

Core Products and Cooperation
Memokath™ Thermally Expandable Metal Stent (Exclusive Distributor in China): Minimally invasive, long-lasting, safe and removable, suitable for the treatment of ureteral, urethral and prostatic obstruction.

EchoLaser Ultrasound-Guided Laser Thermal Ablation System (Exclusive Distributor in China): Precise, visual minimally invasive treatment of prostate diseases.
High-end urological consumables: guide needles, disposable ureteral guide sheaths, endoscopic guide sheaths, etc.

Academics and Brand
Participates in and organizes hundreds of domestic and international academic conferences and departmental meetings every year, continuously promoting clinical exchanges and technology promotion, and winning the trust of many well-known urological experts.

Company Honor
Special Report by Beijing TV (BRTV)
Authoritative recommendation by "Beijing Through Train"
Unanimously recognized by experts at home and abroad

Chenglai Medicine (Beijing) Co.LTD is headquartered in Airport Science and Technology Park, Shunyi District, Beijing. Since its establishment, it has been deeply involved in the field of urology and is committed to becoming a leading comprehensive urological health service provider in China.
In the early stage of development, the company established a long-term strategic partnership with Pnnmedical (an internationally renowned minimally invasive medical research institution) in Denmark and became the exclusive distributor of its Memokath™ series of new thermally expandable metal stent products in China. This series of stents covers multiple parts such as the ureter, urethra, and prostate. It is made of nickel-titanium memory alloy and has the characteristics of minimally invasive implantation, long-lasting support, and safe removability, providing internationally advanced treatment options for patients with urinary tract obstruction.
Subsequently, the company introduced the EchoLaser ultrasound-guided laser thermal ablation system, bringing a minimally invasive, precise, and visual new treatment method for prostate diseases. At the same time, it cooperated with Youkang Technology to introduce a variety of high-end consumables such as guide needles, disposable ureteral guide sheaths, and disposable endoscopic guide sheaths, continuously enriching the product line.
In terms of brand building and academic promotion, the company participates in nearly 100 domestic and international academic conferences every year, and organizes more than 100 departmental meetings and online seminars to promote in-depth understanding of innovative products among medical staff, and gradually establish a high degree of visibility and industry influence in the field of urology, winning the trust of many well-known experts and medical institutions, and becoming an important partner in the field of urinary tract obstruction and minimally invasive prostate treatment.

Authoritative Media Attention
Featured in a special report by Beijing TV (BRTV), Tan Peng, general manager of the company, was invited to introduce new concepts and core products for the treatment of benign prostatic hyperplasia on BRTV Finance Channel, significantly enhancing the brand's influence among the public and the industry.

Industry Platform Recommendation
Listed on the "Beijing Through Train" recommendation list, and received high praise from recommender Chen Jiaqi, further demonstrating the company's professional value and industry recognition in the field of urological medicine.

Unanimous praise from experts
With high-quality products and professional services, it has accumulated an excellent reputation in the industry, and has been recognized and recommended by many well-known domestic and foreign urology experts, becoming a trusted partner in the field of minimally invasive urological treatment.